Merck drug triggers response in 24 percent of lung cancer patients
(Reuters) - Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, showed that about a quarter of...
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/x6kc_Z1uI_U/story01.htm
No comments:
Post a Comment